Project

Immune checkpoint inhibitors (ICI) are anti-tumor immunotherapies that have revolutionized the prognosis of cancers by making late-stage cures possible. To date, however, only a minority of patients respond these new treatments. Our work analyses the extent to which a lack of available energy can explain these failures, and how its restoration can contribute to improved efficacy of ICI treatments. To this end, we measure patients' resting energy expenditure (REE) using indirect calorimetry, and their body composition using DEXA and impedancemetry. We have shown that a high DER (hypermetabolism) is associated with a lower chance of ICI efficacy in patients with non-small cell lung cancer (Boudou-Rouquette, Ebiomedecine 2021) or clear cell renal cell carcinoma (Noel, Cancers 2022). On the other hand, covering caloric needs is associated with better efficacy (Tiako-Meyo, Clin Nutr Espen 2024). 

We are studying 3 main areas of intervention:

  1. Clinical nutrition
  2. Adapted physical activity
  3. Intestinal microbiota

To study all of these questions, we have different clinical studies ongoing:

1. The METABO-1 clinical trial is a randomized study of hypermetabolic patients, investigating the factors influencing hypermetabolism. 

2. The METABO-2 clinical trial compares the energy metabolism of circulating lymphocytes in normo- and hypermetabolic patients. 

3. The MUSCULO-TEP study investigates the effect of physical activity in inducing metabolic flight from tumor cells to muscles. 

4. The NUTRIM-23 randomized trial is studying the efficacy of early nutritional intervention on the effect of immunotherapies. 

Finally, we are participating in a research network using the faeces of patients treated with immunotherapy to study the relationship between their microbiota and the efficacy of ICI response (Derosa, Cell 2024, Derosa, Nat Med 2022).

 

Contact

Pr François Goldwasser

Contact by email